135 research outputs found
Measuring Detailed Chemical Abundances from Co-added Medium-resolution Spectra. I. Tests Using Milky Way Dwarf Spheroidal Galaxies and Globular Clusters
The ability to measure metallicities and α-element abundances in individual red giant branch (RGB) stars using medium-resolution spectra (R ≈ 6000) is a valuable tool for deciphering the nature of Milky Way dwarf satellites and the history of the Galactic halo. Extending such studies to more distant systems like Andromeda is beyond the ability of the current generation of telescopes, but by co-adding the spectra of similar stars, we can attain the necessary signal-to-noise ratio (S/N) to make detailed abundance measurements. In this paper, we present a method to determine metallicities and α-element abundances using the co-addition of medium-resolution spectra. We test the method of spectral co-addition using high-S/N spectra of more than 1300 RGB stars from Milky Way globular clusters and dwarf spheroidal galaxies obtained with the Keck II telescope/DEIMOS spectrograph. We group similar stars using photometric criteria and compare the weighted ensemble average abundances ([Fe/H], [Mg/Fe], [Si/Fe], [Ca/Fe], and [Ti/Fe]) of individual stars in each group with the measurements made on the corresponding co-added spectrum. We find a high level of agreement between the two methods, which permits us to apply this co-added spectra technique to more distant RGB stars, like stars in the M31 satellite galaxies. This paper outlines our spectral co-addition and abundance measurement methodology and describes the potential biases in making these measurements
Reconstruction of Objects by Direct Demodulation
High resolution reconstruction of complicated objects from incomplete and
noisy data can be achieved by solving modulation equations iteratively under
physical constraints. This direct demodulation method is a powerful technique
for dealing with inverse problem in general case. Spectral and image
restorations and computerized tomography are only particular cases of general
demodulation. It is possible to reconstruct an object in higher dimensional
space from observations by a simple lower dimensional instrument through direct
demodulation. Our simulations show that wide field and high resolution images
of space hard X-rays and soft gamma rays can be obtained by a collimated
non-position-sensitive detector without coded aperture masks.Comment: 11 pages, 6 figure
Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer
Prostate cancer is the most common cancer among western men, with a significant mortality and morbidity reported for advanced metastatic disease. Current understanding of metastatic disease is limited due to difficulty of sampling as prostate cancer mainly metastasizes to bone. By analysing prostate cancer bone metastases using high density microarrays, we found a common genomic copy number loss at 6q16.1–16.2, containing the FBXL4 gene, which was confirmed in larger series of bone metastases by fluorescence in situ hybridisation (FISH). Loss of FBXL4 was also detected in primary tumours and it was highly associated with prognostic factors including high Gleason score, clinical stage, prostate-specific antigen (PSA) and extent of disease, as well as poor patient survival, suggesting that FBXL4 loss contributes to prostate cancer progression. We also demonstrated that FBXL4 deletion is detectable in circulating tumour cells (CTCs), making it a potential prognostic biomarker by ‘liquid biopsy’. In vitro analysis showed that FBXL4 plays a role in regulating the migration and invasion of prostate cancer cells. FBXL4 potentially controls cancer metastasis through regulation of ERLEC1 levels. Therefore, FBXL4 could be a potential novel prostate cancer suppressor gene, which may prevent cancer progression and metastasis through controlling cell invasion
Expression of phospholipase C isozymes in human breast cancer and their clinical significance
Phospholipase C (PLC) regulates a number of
cellular behaviours including cell motility, cell transformation,
differentiation and cell growth. PLC plays a regulatory
role in cancer cells partly by acting as signalling intermediates
for cytokines such as EGF and interleukins. The current
study examined the expression of the PLC isozymes in human
breast cancer and corresponding clinical relevance. Transcript
levels of human PLC-α, -β1, -δ, -ε, and -γ1 in human breast
cancer tissues were quantitatively determined by real-time
PCR. Immunochemical staining was performed for PLC-δ.
The clinical relevance was analysed with clinic pathological
information. Mammary tissues widely expressed PLC-α, -β1,
-δ, -ε, and -γ1. Significantly high levels of PLC -β1 and -ε
were seen in breast cancer tissues in comparison with normal
mammary gland tissues. PLC-γ1 however, showed marginally
low levels in tumour tissues. No significant difference was
seen in the expression of the PLC isozymes in tumours with
lymph node metastases. Moderately and poorly differentiated
breast tumours (grade 2 and grade 3) had significantly higher
levels of PLC-γ1, compared with well differentiated tumours.
High levels of PLC-δ were significantly correlated with a
shorter disease-free survival. The altered expression of other
isozymes had no correlation with the survival. It is concluded
that mammary tissues differentially expressed PLC isozymes.
These isozymes have certain implications in the disease development
and progression, with PLC-δ showing a significant
correlation with shorter disease-free survival
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
BACKGROUND: New WHO guidelines recommend ART initiation for HIV-positive persons with CD4 cell counts ≤500 cells/µL, a higher threshold than was previously recommended. Country decision makers must consider whether to further expand ART eligibility accordingly. METHODS: We used multiple independent mathematical models in four settings-South Africa, Zambia, India, and Vietnam-to evaluate the potential health impact, costs, and cost-effectiveness of different adult ART eligibility criteria under scenarios of current and expanded treatment coverage, with results projected over 20 years. Analyses considered extending eligibility to include individuals with CD4 ≤500 cells/µL or all HIV-positive adults, compared to the previous recommendation of initiation with CD4 ≤350 cells/µL. We assessed costs from a health system perspective, and calculated the incremental cost per DALY averted (/DALY was less than the country's per capita gross domestic product (GDP; South Africa: 1425, India: 1407) and 'cost-effective' if 237 to 749/DALY. Results were similar in scenarios with substantially expanded treatment access and for expanding eligibility to all HIV-positive adults. Expanding treatment coverage in the general population was therefore found to be cost-effective. In India, eligibility for all HIV-positive persons ranged from 241/DALY and in Vietnam eligibility for CD4 ≤500 cells/µL cost $290/DALY. In concentrated epidemics, expanded access among key populations was also cost-effective. INTERPRETATION: Earlier ART eligibility is estimated to be very cost-effective in low- and middle-income settings, although these questions should be revisited as further information becomes available. Scaling-up ART should be considered among other high-priority health interventions competing for health budgets. FUNDING: The Bill and Melinda Gates Foundation and World Health Organization
Autoantibodies against type I IFNs in patients with critical influenza pneumonia
In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine. Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially in pMMR disease. METHODS This phase III, global, double-blind, placebo-controlled trial randomly assigned eligible patients with newly diagnosed advanced or recurrent endometrial cancer 1:1:1 to: carboplatin/paclitaxel plus durvalumab placebo followed by placebo maintenance (control arm); carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib placebo (durvalumab arm); or carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib (durvalumab + olaparib arm). The primary end points were progression-free survival (PFS) in the durvalumab arm versus control and the durvalumab + olaparib arm versus control. RESULTS Seven hundred eighteen patients were randomly assigned. In the intention-to-treat population, statistically significant PFS benefit was observed in the durvalumab (hazard ratio [HR], 0.71 [95% CI, 0.57 to 0.89]; P = .003) and durvalumab + olaparib arms (HR, 0.55 [95% CI, 0.43 to 0.69]; P < .0001) versus control. Prespecified, exploratory subgroup analyses showed PFS benefit in dMMR (HR [durvalumab v control], 0.42 [95% CI, 0.22 to 0.80]; HR [durvalumab + olaparib v control], 0.41 [95% CI, 0.21 to 0.75]) and pMMR subgroups (HR [durvalumab v control], 0.77 [95% CI, 0.60 to 0.97]; HR [durvalumab + olaparib v control] 0.57; [95% CI, 0.44 to 0.73]); and in PD-L1-positive subgroups (HR [durvalumab v control], 0.63 [95% CI, 0.48 to 0.83]; HR [durvalumab + olaparib v control], 0.42 [95% CI, 0.31 to 0.57]). Interim overall survival results (maturity approximately 28%) were supportive of the primary outcomes (durvalumab v control: HR, 0.77 [95% CI, 0.56 to 1.07]; P = .120; durvalumab + olaparib v control: HR, 0.59 [95% CI, 0.42 to 0.83]; P = .003). The safety profiles of the experimental arms were generally consistent with individual agents. CONCLUSION Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with or without olaparib demonstrated a statistically significant and clinically meaningful PFS benefit in patients with advanced or recurrent endometrial cancer
- …